<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38696536</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>PLoS pathogens</Title><ISOAbbreviation>PLoS Pathog</ISOAbbreviation></Journal><ArticleTitle>Major Group-B Enterovirus populations deleted in the noncoding 5' region of genomic RNA modulate activation of the type I interferon pathway in cardiomyocytes and induce myocarditis.</ArticleTitle><Pagination><StartPage>e1012125</StartPage><MedlinePgn>e1012125</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1012125</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1012125</ELocationID><Abstract><AbstractText>Major 5'-terminally deleted (5'TD) RNA forms of group-B coxsackievirus (CVB-5'TD) has been associated with myocarditis in both mice and humans. Although it is known that interferon-β (IFN-β) signaling is critical for an efficient innate immune response against CVB-induced myocarditis, the link between CVB-5'TD RNA forms and type I IFN signaling in cardiomyocytes remains to be explored. In a mouse model of CVB3/28-induced myocarditis, major early-emerging forms of CVB-5'TD RNA have been characterized as replicative viral populations that impair IFN-β production in the heart. Synthetic CVB3/28 RNA forms mimicking each of these major 5'TD virus populations were transfected in mice and have been shown to modulate innate immune responses in the heart and to induce myocarditis in mice. Remarkably, transfection of synthetic viral RNA with deletions in the secondary structures of the 5'-terminal CVB3 RNA domain I, modifying stem-loops "b", "c" or "d", were found to impair IFN-β production in human cardiomyocytes. In addition, the activation of innate immune response by Poly(I:C), was found to restore IFN-β production and to reduce the burden of CVB-5'TD RNA-forms in cardiac tissues, thereby reducing the mortality rate of infected mice. Overall, our results indicate that major early-emerging CVB3 populations deleted in the domain I of genomic RNA, in the 5' noncoding region, modulate the activation of the type I IFN pathway in cardiomyocytes and induce myocarditis in mice. These findings shed new light on the role of replicative CVB-5'TD RNA forms as key pathophysiological factors in CVB-induced human myocarditis.</AbstractText><CopyrightInformation>Copyright: © 2024 Callon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Callon</LastName><ForeName>Domitille</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Reims Champagne Ardennes, Inserm, UMR-S1320 CardioVir, Reims, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Hospital of Reims, Robert Debré, Pathology Department, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glenet</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Reims Champagne Ardennes, Inserm, UMR-S1320 CardioVir, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebreil</LastName><ForeName>Anne-Laure</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>University of Reims Champagne Ardennes, Inserm, UMR-S1320 CardioVir, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heng</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Reims Champagne Ardennes, Inserm, UMR-S1320 CardioVir, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouland</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Academic Hospital of Reims, Robert Debré, Pathology Department, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fichel</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Academic Hospital of Reims, Robert Debré, Pathology Department, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornes</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Reims Champagne Ardennes, Inserm, UMR-S1320 CardioVir, Reims, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Hospital of Reims, Robert Debré, Pathology Department, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreoletti</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Reims Champagne Ardennes, Inserm, UMR-S1320 CardioVir, Reims, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Hospital of Reims, Robert Debré, Virology Department, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berri</LastName><ForeName>Fatma</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of Reims Champagne Ardennes, Inserm, UMR-S1320 CardioVir, Reims, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Pathog</MedlineTA><NlmUniqueID>101238921</NlmUniqueID><ISSNLinking>1553-7366</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="Y">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="Y">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="Y">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="Y">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020121" MajorTopicYN="N">5' Untranslated Regions</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>15</Day><Hour>5</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>2</Day><Hour>18</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>2</Day><Hour>13</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38696536</ArticleId><ArticleId IdType="pmc">PMC11093299</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1012125</ArticleId><ArticleId IdType="pii">PPATHOGENS-D-23-01457</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baggen J, Thibaut HJ, Strating JRPM, Kuppeveld FJM van. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol. 2018; 16(6):368–381. doi: 10.1038/s41579-018-0005-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Genoni A, Canducci F, Rossi A, et al.. Revealing enterovirus infection in chronic human disorders: An integrated diagnostic approach. Sci Rep. 2017; 7(1):5013. doi: 10.1038/s41598-017-04993-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04993-y</ArticleId><ArticleId IdType="pmc">PMC5504018</ArticleId><ArticleId IdType="pubmed">28694527</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy S, Smithee S, Alhazmi A, Chapman N. Coxsackievirus can persist in murine pancreas by deletion of 5′ terminal genomic sequences: Coxsackievirus Persistence in the Pancreas. J Med Virol. 2015; 87(2):240–247.</Citation><ArticleIdList><ArticleId IdType="pubmed">25111164</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam PE, Fontana DR, Messner RP. Coxsackievirus B1–induced chronic inflammatory myopathy: differences in induction of autoantibodies to muscle and nuclear antigens by cloned myopathic and amyopathic viruses. J Lab Clin Med. 2003; 142(3):196–204. doi: 10.1016/S0022-2143(03)00108-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2143(03)00108-2</ArticleId><ArticleId IdType="pubmed">14532908</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM, Kim K-S, Drescher KM, Oka K, Tracy S. 5’ terminal deletions in the genome of a coxsackievirus B2 strain occurred naturally in human heart. Virology. 2008; 375(2):480–491. doi: 10.1016/j.virol.2008.02.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.02.030</ArticleId><ArticleId IdType="pmc">PMC2440640</ArticleId><ArticleId IdType="pubmed">18378272</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouin A, Nguyen Y, Wehbe M, et al.. Major Persistent 5′ Terminally Deleted Coxsackievirus B3 Populations in Human Endomyocardial Tissues. Emerg Infect Dis. 2016; 22(8):1488–1490. doi: 10.3201/eid2208.160186</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2208.160186</ArticleId><ArticleId IdType="pmc">PMC4982168</ArticleId><ArticleId IdType="pubmed">27434549</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenet M, N’Guyen Y, Mirand A, et al.. Major 5′terminally deleted enterovirus populations modulate type I IFN response in acute myocarditis patients and in human cultured cardiomyocytes. Sci Rep. Nature Publishing Group; 2020; 10(1):11947. doi: 10.1038/s41598-020-67648-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-67648-5</ArticleId><ArticleId IdType="pmc">PMC7371739</ArticleId><ArticleId IdType="pubmed">32686697</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouin A, Gretteau P-A, Wehbe M, et al.. Enterovirus Persistence in Cardiac Cells of Patients With Idiopathic Dilated Cardiomyopathy Is Linked to 5’ Terminal Genomic RNA-Deleted Viral Populations With Viral-Encoded Proteinase Activities. Circulation. 2019; 139(20):2326–2338. doi: 10.1161/CIRCULATIONAHA.118.035966</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.035966</ArticleId><ArticleId IdType="pmc">PMC6517084</ArticleId><ArticleId IdType="pubmed">30755025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K-S, Tracy S, Tapprich W, et al.. 5’-Terminal Deletions Occur in Coxsackievirus B3 during Replication in Murine Hearts and Cardiac Myocyte Cultures and Correlate with Encapsidation of Negative-Strand Viral RNA. J Virol. 2005; 79(11):7024–7041. doi: 10.1128/JVI.79.11.7024-7041.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.11.7024-7041.2005</ArticleId><ArticleId IdType="pmc">PMC1112132</ArticleId><ArticleId IdType="pubmed">15890942</ArticleId></ArticleIdList></Reference><Reference><Citation>Callon D, Lebreil A-L, Bouland N, et al.. Early Emergence of 5′ Terminally Deleted Coxsackievirus-B3 RNA Forms Is Associated with Acute and Persistent Infections in Mouse Target Tissues. Vaccines. 2022; 10(8):1203. doi: 10.3390/vaccines10081203</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10081203</ArticleId><ArticleId IdType="pmc">PMC9413645</ArticleId><ArticleId IdType="pubmed">36016091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lévêque N, Garcia M, Bouin A, et al.. Functional Consequences of RNA
5′-Terminal Deletions on Coxsackievirus B3 RNA Replication and Ribonucleoprotein Complex Formation. Pfeiffer JK, editor. J Virol [Internet]. 2017.  [cited 2019 Jan 15]; 91(16). Available from: http://jvi.asm.org/lookup/doi/10.1128/JVI.00423-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00423-17</ArticleId><ArticleId IdType="pmc">PMC5533909</ArticleId><ArticleId IdType="pubmed">28539455</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenet M, Heng L, Callon D, et al.. Structures and Functions of Viral 5′ Non-Coding Genomic RNA Domain-I in Group-B Enterovirus Infections. Viruses. 2020; 12(9):919. doi: 10.3390/v12090919</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12090919</ArticleId><ArticleId IdType="pmc">PMC7552046</ArticleId><ArticleId IdType="pubmed">32839386</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM. Persistent Enterovirus Infection: Little Deletions, Long Infections. Vaccines. Multidisciplinary Digital Publishing Institute; 2022; 10(5):770. doi: 10.3390/vaccines10050770</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050770</ArticleId><ArticleId IdType="pmc">PMC9143164</ArticleId><ArticleId IdType="pubmed">35632526</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, Hato SV, Langereis MA, et al.. MDA5 detects the double-stranded RNA replicative form in picornavirus-infected cells. Cell Rep. 2012; 2(5):1187–1196. doi: 10.1016/j.celrep.2012.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2012.10.005</ArticleId><ArticleId IdType="pmc">PMC7103987</ArticleId><ArticleId IdType="pubmed">23142662</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, Langereis MA, Olagnier D, et al.. Coxsackievirus Cloverleaf RNA Containing a 5′ Triphosphate Triggers an Antiviral Response via RIG-I Activation. Thiel V, editor. PLoS ONE. 2014; 9(4):e95927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3997492</ArticleId><ArticleId IdType="pubmed">24759703</ArticleId></ArticleIdList></Reference><Reference><Citation>Rainer Wessely, Karin Klingel, Knowlton Kirk U., Kandolf Reinhard. Cardioselective Infection With Coxsackievirus B3 Requires Intact Type I Interferon Signaling. Circulation. American Heart Association; 2001; 103(5):756–761.</Citation><ArticleIdList><ArticleId IdType="pubmed">11156890</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlton Kirk U. Dilated Cardiomyopathy. Circulation. American Heart Association; 2019; 139(20):2339–2341. doi: 10.1161/CIRCULATIONAHA.119.040037</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.119.040037</ArticleId><ArticleId IdType="pubmed">31082299</ArticleId></ArticleIdList></Reference><Reference><Citation>Althof N, Harkins S, Kemball CC, Flynn CT, Alirezaei M, Whitton JL. In Vivo Ablation of Type I Interferon Receptor from Cardiomyocytes Delays Coxsackieviral Clearance and Accelerates Myocardial Disease. J Virol. 2014; 88(9):5087–5099. doi: 10.1128/JVI.00184-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00184-14</ArticleId><ArticleId IdType="pmc">PMC3993796</ArticleId><ArticleId IdType="pubmed">24574394</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose NR. Critical Cytokine Pathways to Cardiac Inflammation. J Interferon Cytokine Res. 2011; 31(10):705–710. doi: 10.1089/jir.2011.0057</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2011.0057</ArticleId><ArticleId IdType="pmc">PMC3189548</ArticleId><ArticleId IdType="pubmed">21861699</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj Deonarain, Dante Cerullo, Koichi Fuse, Liu Peter P., Fish Eleanor N. Protective Role for Interferon-β in Coxsackievirus B3 Infection. Circulation. American Heart Association; 2004; 110(23):3540–3543.</Citation><ArticleIdList><ArticleId IdType="pubmed">15249500</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassner D, Siegismund CS, Kühl U, et al.. CCR5del32 genotype in human enteroviral cardiomyopathy leads to spontaneous virus clearance and improved outcome compared to wildtype CCR5.
J Transl Med [Internet]. 2018.  [cited 2019 Mar 5]; 16(1). Available from: https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1610-8

</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1610-8</ArticleId><ArticleId IdType="pmc">PMC6123922</ArticleId><ArticleId IdType="pubmed">30180856</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh S-J, Lim B-K, Yun J, Shin OS. CVB3-Mediated Mitophagy Plays an Important Role in Viral Replication via Abrogation of Interferon Pathways. Front Cell Infect Microbiol. 2021; 11:704494. doi: 10.3389/fcimb.2021.704494</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.704494</ArticleId><ArticleId IdType="pmc">PMC8292102</ArticleId><ArticleId IdType="pubmed">34295842</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JP, Cerny A, Asher DR, Kurt-Jones EA, Bronson RT, Finberg RW. MDA5 and MAVS Mediate Type I Interferon Responses to Coxsackie B Virus. J Virol. 2010; 84(1):254–260. doi: 10.1128/JVI.00631-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00631-09</ArticleId><ArticleId IdType="pmc">PMC2798442</ArticleId><ArticleId IdType="pubmed">19846534</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson EB, Yamada DH, Elsaesser H, et al.. Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection. Science. 2013; 340(6129):202–207. doi: 10.1126/science.1235208</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1235208</ArticleId><ArticleId IdType="pmc">PMC3704950</ArticleId><ArticleId IdType="pubmed">23580528</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesev EV, LeDesma RA, Ploss A. Decoding type I and III interferon signalling during viral infection. Nat Microbiol. 2019; 4(6):914–924. doi: 10.1038/s41564-019-0421-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-019-0421-x</ArticleId><ArticleId IdType="pmc">PMC6554024</ArticleId><ArticleId IdType="pubmed">30936491</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniak S, Owens AP, Baunacke M, et al.. PAR-1 contributes to the innate immune response during viral infection. J Clin Invest. 2013; 123(3):1310–1322. doi: 10.1172/JCI66125</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI66125</ArticleId><ArticleId IdType="pmc">PMC3582138</ArticleId><ArticleId IdType="pubmed">23391721</ArticleId></ArticleIdList></Reference><Reference><Citation>Reikine S, Nguyen JB, Modis Y. Pattern Recognition and Signaling Mechanisms of RIG-I and MDA5.
Front Immunol [Internet]. 2014.  [cited 2019 Feb 25]; 5. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2014.00342/abstract

</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00342/abstract</ArticleId><ArticleId IdType="pmc">PMC4107945</ArticleId><ArticleId IdType="pubmed">25101084</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H, Takeuchi O, Sato S, et al.. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006; 441(7089):101–105. doi: 10.1038/nature04734</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04734</ArticleId><ArticleId IdType="pubmed">16625202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hato SV, Ricour C, Schulte BM, et al.. The mengovirus leader protein blocks interferon-α/β gene transcription and inhibits activation of interferon regulatory factor 3. Cell Microbiol. 2007; 9(12):2921–2930.</Citation><ArticleIdList><ArticleId IdType="pubmed">17991048</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempf BJ, Barton DJ. Poliovirus 2A(Pro) increases viral mRNA and polysome stability coordinately in time with cleavage of eIF4G. J Virol. 2008; 82(12):5847–5859. doi: 10.1128/JVI.01514-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01514-07</ArticleId><ArticleId IdType="pmc">PMC2395153</ArticleId><ArticleId IdType="pubmed">18400852</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001; 413(6857):732–738. doi: 10.1038/35099560</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35099560</ArticleId><ArticleId IdType="pubmed">11607032</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Li M, Song Y, Xu W. TRIM21 Restricts Coxsackievirus B3 Replication, Cardiac and Pancreatic Injury via Interacting With MAVS and Positively Regulating IRF3-Mediated Type-I Interferon Production. Front Immunol [Internet]. 2018.  [cited 2020 Apr 3]; 9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209670/
doi: 10.3389/fimmu.2018.02479

</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02479</ArticleId><ArticleId IdType="pmc">PMC6209670</ArticleId><ArticleId IdType="pubmed">30410495</ArticleId></ArticleIdList></Reference><Reference><Citation>Peersen OB. Picornaviral polymerase structure, function, and fidelity modulation. Virus Res. 2017; 234:4–20. doi: 10.1016/j.virusres.2017.01.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2017.01.026</ArticleId><ArticleId IdType="pmc">PMC5476519</ArticleId><ArticleId IdType="pubmed">28163093</ArticleId></ArticleIdList></Reference><Reference><Citation>Callon D, Guedra A, Lebreil A-L, et al.. Replication Activities of Major 5’ Terminally Deleted Group-B Coxsackievirus RNA Forms Decrease PCSK2 mRNA Expression Impairing Insulin Maturation in Pancreatic Beta Cells. Viruses. 2022; 14(12):2781. doi: 10.3390/v14122781</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122781</ArticleId><ArticleId IdType="pmc">PMC9788552</ArticleId><ArticleId IdType="pubmed">36560784</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertel KJ, Brunner JE, Semler BL. Mechanistic Consequences of hnRNP C Binding to Both RNA Termini of Poliovirus Negative-Strand RNA Intermediates. J Virol. 2010; 84(9):4229–4242. doi: 10.1128/JVI.02198-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02198-09</ArticleId><ArticleId IdType="pmc">PMC2863767</ArticleId><ArticleId IdType="pubmed">20164237</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner JE, Ertel KJ, Rozovics JM, Semler BL. Delayed kinetics of poliovirus RNA synthesis in a human cell line with reduced levels of hnRNP C proteins. Virology. 2010; 400(2):240–247. doi: 10.1016/j.virol.2010.01.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2010.01.031</ArticleId><ArticleId IdType="pmc">PMC2844484</ArticleId><ArticleId IdType="pubmed">20189623</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K-S, Chapman NM, Tracy S. Replication of Coxsackievirus B3 in Primary Cell Cultures Generates Novel Viral Genome Deletions. J Virol. 2008; 82(4):2033–2037. doi: 10.1128/JVI.01774-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01774-07</ArticleId><ArticleId IdType="pmc">PMC2258713</ArticleId><ArticleId IdType="pubmed">18057248</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamma H, Portman DS, Dreyfuss G. Cell Type-Specific Expression of hnRNP Proteins. Exp Cell Res. 1995; 221(1):187–196. doi: 10.1006/excr.1995.1366</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/excr.1995.1366</ArticleId><ArticleId IdType="pubmed">7589244</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu Z, Chapman NM, Hufnagel G, et al.. The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5’ nontranslated region. J Virol. 1995; 69(8):4607–4618. doi: 10.1128/JVI.69.8.4607-4618.1995</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.69.8.4607-4618.1995</ArticleId><ArticleId IdType="pmc">PMC189260</ArticleId><ArticleId IdType="pubmed">7609025</ArticleId></ArticleIdList></Reference><Reference><Citation>Saarinen NVV, Laiho JE, Richardson SJ, et al.. A novel rat CVB1-VP1 monoclonal antibody 3A6 detects a broad range of enteroviruses. Sci Rep. 2018; 8(1):33. doi: 10.1038/s41598-017-18495-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-18495-4</ArticleId><ArticleId IdType="pmc">PMC5758616</ArticleId><ArticleId IdType="pubmed">29311608</ArticleId></ArticleIdList></Reference><Reference><Citation>Caforio ALP, Pankuweit S, Arbustini E, et al.. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013; 34(33):2636–2648. doi: 10.1093/eurheartj/eht210</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/eht210</ArticleId><ArticleId IdType="pubmed">23824828</ArticleId></ArticleIdList></Reference><Reference><Citation>Andréoletti L, Hober D, Becquart P, et al.. Experimental CVB3-induced chronic myocarditis in two murine strains: evidence of interrelationships between virus replication and myocardial damage in persistent cardiac infection. J Med Virol. 1997; 52(2):206–214. doi: 10.1002/(sici)1096-9071(199706)52:2&amp;lt;206::aid-jmv15&amp;gt;3.0.co;2-i</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1096-9071(199706)52:2&amp;lt;206::aid-jmv15&amp;gt;3.0.co;2-i</ArticleId><ArticleId IdType="pubmed">9179770</ArticleId></ArticleIdList></Reference><Reference><Citation>N’Guyen Y, Lesaffre F, Metz D, et al.. Enterovirus but not Parvovirus B19 is associated with idiopathic dilated cardiomyopathy and endomyocardial CD3, CD68, or HLA-DR expression. J Med Virol. 2017; 89(1):55–63. doi: 10.1002/jmv.24600</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24600</ArticleId><ArticleId IdType="pubmed">27301802</ArticleId></ArticleIdList></Reference><Reference><Citation>Lévêque N, Renois F, Talmud D, et al.. Quantitative Genomic and Antigenomic Enterovirus RNA Detection in Explanted Heart Tissue Samples from Patients with End-Stage Idiopathic Dilated Cardiomyopathy. J Clin Microbiol. 2012; 50(10):3378–3380. doi: 10.1128/JCM.01612-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01612-12</ArticleId><ArticleId IdType="pmc">PMC3457437</ArticleId><ArticleId IdType="pubmed">22837323</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>